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Introduction
The variety of form and function in inositides (inositol lipids and phosphates) stems largely from
the degree and isomeric speciﬁcity of phosphorylation of their common inositol ring. Thus their
synthesis, and its differential regulation, lie primarily in the large family of kinases that phos-
phorylate the inositol ring. In a previous review in this publication (Irvine et al., 2006) we addressed
the inositol phosphate kinases, with a speciﬁc focus on the Ins(1,4,5)P3 3-kinase family. Here we
turn to the inositol lipid kinases, with a speciﬁc focus on the phosphatidylinositol phosphate
kinases. These are the family of enzymes that synthesize phosphatidylinositol 4,5-bisphosphate
(PtdIns(4,5)P2) (Fig. 1). The Type I enzymes (EC 2.7.1.68) are now known to catalyze the major route
of PtdIns(4,5)P2 synthesis, the 5-phosphorylation of PtdIns4P (Rameh et al., 1997), and are here
abbreviated as Type I PtdIns4P 5-kinases (PtdIns4P 5-kinases Ia, Ib and Ig). The Type II enzymes (EC
2.7.1.149) are 4-kinases (Rameh et al., 1997), whose preferred substrate (Rameh et al., 1997; Morris
et al., 2000; Roberts et al., 2005) is PtdIns5P. They will be abbreviated here as PtdIns5P 4-kinases IIa,
IIb and IIg.Type II PtdIns5P 4-kinases
Type II PtdIns5P 4-kinases – basic functions
Although there has been some discussion about the potential functions of the Type II enzymes,
there is an emerging consensus that their major function is to regulate the levels of their substrate,
PtdIns5P. The amount of PtdIns(4,5)P2 that they will synthesize relative to the Type I enzymes is likely
to be small (mostly because PtdIns5P is present at much lower levels than PtdIns4P (Roberts et al.,
2005)). Also, the recent discovery and cloning in Majerus’ lab of two isoforms of PtdIns(4,5)P2* Corresponding author.
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Fig. 1. The PtdInsP kinases. The inositol lipids and kinases that are the principal topics of discussion in this review are illustrated
here. EC Numbers: Type I PtdIns4P 5-kinase, EC 2.7.1.68; Type II PtdIns5P 4-kinase, EC 2.7.1.149; PtdIns(4,5)P2 4-phosphatase, EC
3.1.3.78.
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(Zou et al., 2007) (see below for the signiﬁcance of this) generates a very plausible cycle for the
generation of PtdIns5P (by a PtdIns(4,5)P2 4-phosphatase) and its removal (by a Type II PtdIns5P
4-kinase). Lecompte et al. (2008) have suggested an interesting evolutionary pathway for the
appearance of this cycle – that PtdIns5P generation and removal may occur by different routes
involving different combinations of enzymes (e.g. from PtdIns via Type III PtdIns3P 5-kinase and
myotubularin) and that the PtdIns(4,5)P2 4-phosphatase/Type II PtdIns5P 4-kinase ‘cycle’ may be the
latest of these to evolve, and is conﬁned to metazoans. It is worth noting in this context that the
signiﬁcance of a PTEN homologue that is a 5-phosphatse (EC 3.1.3.36), but very speciﬁc for PtdIns5P
(Pagliarini et al., 2004), remains to be explored fully – is this an alternative way of removing PtdIns5P,
and if so, how does it ﬁt in with the Type II PtdIns5P 4-kinases?PtdIns5P
The functions of PtdIns5P are being actively explored, and it seems likely that our list of these is far
from complete. This is a pertinent place to point out an error in our description of the mass assay for
PtdIns5P, which we described in Roberts et al. (2005). This was a reﬁnement of the original assay
(Morris et al., 2000), and included, after loading the neomycin beads with lipids, a prior rinse with
‘50 mM Ammonium formate’, before two elutions of inositol lipids with ‘2 M TEAB’ (Triethylammo-
nium bicarbonate). Both these two solutions were described as if they were made up inwater, but they
should of course have been described as being mixed with chloroform and methanol as with the other
bead-elution solutions used in this protocol. Thus they are respectively: CHCl3:CH3OH:Ammonium
Formate 5:10:2 by volume (ﬁnal concentration of formate 50 mM); and CHCl3:CH3OH:2 M TEAB 5:10:2
by volume (ﬁnal concentration of TEAB 0.55 M). This latter solution (with slightly altered
CHCl3:CH3OH:2 M TEAB proportions), is correctly described by Zou et al. (2007), who also successfully
used a more widely available type of glass bead for this experimental procedure.
To return to PtdIns5P functions, in the cytosol its principal effect has been suggested to be to
increase Akt activation (Pendaries et al., 2006), perhaps by inhibiting its dephosphorylation (Ramel
et al., 2009) or the dephosphorylation of PtdIns(3,4,5)P3 (Carricaburu et al., 2003). Recently two
putative PtdIns5P effectors, Dok-1 and Dok-2 were described in T cells (Guittard et al., 2009), and the
signiﬁcance of these will be an interesting area for future exploration. A better understood aspect of
PtdIns5P function is in the nucleus, where ING-2 has been identiﬁed as an effector (Gozani et al., 2003).
Divecha’s group have put together a convincing case that PtdIns5P 4-kinase IIb regulates the levels of
nuclear PtdIns5P (Jones et al., 2006), whereby stressing cells activates p38 MAP kinase, which phos-
phorylates PtdIns5P 4-kinase IIb on two Ser residues causing its inhibition, and thus PtdIns5P increases.
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generating enzyme Type I PtdIns(4,5)P2 4-phosphatase (Zou et al., 2007). So, what regulates the
nuclear localization of PtdIns5P 4-kinase IIb, and is this the only Type II enzyme involved? We have
made some interesting observations in this context recently, which we will brieﬂy summarize here.
PtdIns5P 4-kinases IIa and IIb
Although there have been some indications that endogenous PtdIns5P 4-kinase IIa may be partly
nuclear (Divecha et al., 1993; Boronenkov et al., 1998), extensive studies on transfected cells have
shown that the IIa and IIb isoforms are respectively cytosolic and nuclear, with the latter being
localized by a unique nuclear localization sequence consisting of an acidic a-helix (Ciruela et al., 2000;
Clarke et al., 2007). Moreover, tagging the endogenous PtdIns5P 4-kinase IIb by genomic tagging in
DT40 cells (see below) conﬁrmed that the endogenous enzyme appeared to be entirely nuclear, within
the limits of the cell fractionation procedure employed (Richardson et al., 2007). However, a nuclear
localization for PtdIns5P 4-kinase IIb sat at odds with the phenotype of the knockout mouse (Lamia
et al., 2004) complemented by transfection studies with PtdIns5P 4-kinase IIb, both of which pointed to
a predominantly cytoplasmic role for this enzyme (Carricaburu et al., 2003).
We have recently used genomic tagging in DT40 cells to begin to resolve some of these contra-
dictions and to throw a new light on the relationship between these two Type II PtdIns5P 4-kinase
isoforms (M.W., N. Bond, J. Richardson, K. Lilley, R.F.I. and J.H.C unpublished observations). In brief, we
have found that PtdIns5P 4-kinases IIa and IIb heterodimerize, such that a signiﬁcant proportion of IIa
is nuclear. Moreover, the enzymic activity of the IIa is much greater than that of IIb, so it is possible that
a, or the, major function of the IIb isoform is simply to target the IIa to the nucleus. This is particularly
interesting in the light of the evidence, based on mRNA levels, that in most tissues, indeed, in all that
were studied except spleen, the IIb isoform is more highly expressed than the IIa (Clarke et al., 2008).
Note that spleen is a site of synthesis of B cells (of which DT40s are, indirectly, an example), and T
cells, so it is interesting that, as described above, Guittard et al. (2009) have recently discovered two
new, cytoplasmic, putative PtdIns5P effectors in T cells. The spleen is also the site of synthesis of
erythrocytes and platelets, from which PtdIns5P 4-kinase IIa was ﬁrst puriﬁed and cloned by Bor-
onenkov and Anderson (1995) and Divecha et al. (1995) respectively. Another intriguing link between
erythrocytes and PtdIns5P 4-kinase IIa has emerged recently in a pair of a-thalassemic twins with very
different b-globin gene expression levels, in which the only other gene showing a similar disparity in
expression in their reticulocytes was PtdIns5P 4-kinase IIa (Wenning et al., 2009).
This emphasis on PtdIns5P 4-kinase IIa in blood cells makes a contrast with all other tissues so
far investigated in this context, where PtdIns5P 4-kinase IIbmRNA is dominant over that for PtdIns5P
4-kinase IIa (Clarke et al., 2008). It throws open the possibility that in many tissues most PtdIns5P
4-kinase IIa is nuclear, and this will be especially so in muscle and liver (Clarke et al., 2008). This in turn
sheds an alternative light on the experiments discussed above where PtdIns5P 4-kinase IIb levels were
manipulated (Carricaburu et al., 2003; Lamia et al., 2004), in that perhaps themajor effect of decreasing
PtdIns5P 4-kinase IIb is to increase cytosolic IIa because there is no IIb to take it to the nucleus. Of
course we don’t yet know if IIa/IIb heterodimers are localized within the nucleus in the same place as
IIb/IIb homodimers, nor whether they have distinct functions, and overall our discovery of this het-
erodimerization asks more questions than it answers. But that is what makes it interesting.
PtdIns5P 4-kinase IIg
This has been the ‘Cinderella’ member of the family until recently, and we have been investigating
some of its basic biology and biochemistry, which we summarize here.
When ﬁrst cloned by Itoh et al. (1998), PtdIns5P 4-kinase IIg was described as being highly
expressed in kidney, localized to the endoplasmic reticulum, and phosphorylated when cells were
stimulated by mitogens. We have conﬁrmed that kidney expresses PtdIns5P 4-kinase IIg more highly
than any other tissue – as judged by mRNA levels, kidney is unique in expressing more PtdIns5P
4-kinase IIg than PtdIns5P 4-kinase IIa and IIb combined (Clarke et al., 2008). Even more striking is the
localization of expression within the kidney, as PtdIns5P 4-kinase IIg is largely conﬁned to epithelial
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The distribution of PtdIns5P 4-kinase IIg in nervous tissue, the other type of tissue in which it is
highly expressed (Clarke et al., 2008), shows a similar restricted and well deﬁned expression in the
brain and also the spinal cord (Clarke et al., 2009). This expression is limited to neurons, particularly the
cerebellar Purkinje cells, pyramidal cells of the hippocampus, large neuronal cell-types in the cerebral
cortex including pyramidal cells, and mitral cells in the olfactory bulb, but is not expressed in cere-
bellar, hippocampal formation or olfactory bulb granule cells (Clarke et al., 2009).
These distinct and speciﬁc expression patterns in brain and kidney will eventually tell us something
of its function, though at present this is difﬁcult to guess. However, two other properties of PtdIns5P
4-kinase IIg point a way forward in understanding what it does. Firstly, in both kidney (Clarke et al.,
2008) and brain (Clarke et al., 2009) it shows the same intracellular distribution: it appears to be
associated with vesicles, which in kidney epithelial cells are concentrated towards the secreting end of
the cells (Clarke et al., 2008).
We do not yet know the nature of these vesicles. In neurons PtdIns5P 4-kinase IIg shows a partial
colocalization with markers of cellular compartments of the endomembrane trafﬁcking pathway
(Clarke et al., 2009), and transfection experiments with mildly permeabilized HeLa cells showed
a partial colocalization with Golgi markers such as GM130 and golgin 160, as well as the endosomal
marker EEA1, but after more extensive cell permeabilization these correlations were decreased (Clarke
et al., 2009). In transfected kidney cell lines (Clarke et al., 2008), PtdIns5P 4-kinase IIg was again
partially colocalized with GM130, but not with endoplasmic reticulum or ERGIC markers, and the
GM130 relationship survived Brefeldin A treatment of the cells.Fig. 2. PtdIns5P 4-kinase IIg expression in the adult mouse kidney. An antibody speciﬁc to PtdIns5P 4-kinase IIg was used in tissue
immunohistochemistry to identify endogenous expression in kidney sections; for details see (Clarke et al., 2008). A) PtdIns5P
4-kinase IIg in a whole saggital kidney section (scale bar¼ 1 mm). B) PtdIns5P 4-kinase IIg in a representative strip showing
differential PtdIns5P 4-kinase IIg expression from outer capsule to calyx (scale bar¼ 250 mm). C) Inset slides show PtdIns5P 4-kinase
IIg in the cortex, outer and inner medulla. The PtdIns5P 4-kinase IIg signal is restricted to speciﬁc cells within these regions (scale
bar¼ 40 mm).
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ﬁcking linked with the Golgi apparatus. In the kidney this would be associated with the business of
inserting and removing plasma membrane transporters and channels, and in the brain either traf-
ﬁcking of vesicles along neuronal processes or perhaps the delivery/insertion of channels and trans-
porters to their correct locations. PtdIns(4,5)P2 is of course known to be associated with the regulation
of activity and trafﬁcking of ion channels and transporters, but returning to the low levels of PtdIns5P
compared to PtdIns4P in cells plus the evidence discussed above for possible roles of PtdIns5P in other
cellular functions, we think it much more likely that PtdIns5P is the active molecule in whatever
vesicular processing/transporting events PtdIns5P 4-kinase IIg is regulating.
Secondly, there is another aspect of PtdIns5P 4-kinase IIg biochemistry which may point to how it
functions – actually it is two properties that suggest the same thing. PtdIns5P 4-kinase IIg is, when
bacterially expressed, catalytically close to inactive (Clarke et al., 2008); it has even less activity than
PtdIns5P 4-kinase IIb (above). But when immunoprecipitated from eukaryotic cells, PtdIns5P 4-kinase
IIg does show some catalytic activity, which can be accounted for by its association with PtdIns5P
4-kinase IIa, an association that we have demonstrated directly in vitro (Clarke et al., 2008). Thus we
can see a parallel with the PtdIns5P 4-kinase IIa/IIb heterodimerization that we have discussed above,
and our current working hypothesis for PtdIns5P 4-kinase IIg is that it is associated with a sub-pop-
ulation of vesicles in the cell trafﬁcking system, and by heterodimerizationwith PtdIns5P 4-kinase IIa it
targets the latter enzyme to the relevant vesicles, where it regulates PtdIns5P levels for a function yet to
be deﬁned (see above). We should note also that there is still the possibility that by associating with
a Type I PtdIns4P 5-kinase activity (Hinchliffe et al., 2002), PtdIns5P 4-kinase IIamay also target one of
these enzymes to the relevant vesicles (discussed further below), so PtdIns(4,5)P2 might yet be
a relevant signal in this context too.
So our recent data are painting a different picture of Type II PtdIns5P 4-kinase function and regu-
lation from that which we have had before. We can suggest the possibility that PtdIns5P 4-kinase IIa is
the (possibly the only signiﬁcantly) active enzyme of the three isoforms, and that it may have its own
individual function(s) in cells. Additionally it can be targeted by the other isoforms, to the nucleus by
PtdIns5P 4-kinase IIb, or to trafﬁcking/secretory vesicles by PtdIns5P 4-kinase IIg. This picture paints
a remarkable (and we suspect unique) relationship between three isoforms of the same lipid kinase
family.
Association between Type I and Type II PtdInsP kinases
Before leaving the subject of the heterodimerization of Type II PtdIns5P 4-kinases, another
dimerization (or at least, association) needs discussing in this context, which is the association of
PtdIns5P 4-kinase IIa with Type I PtdIns4P 5-kinases. This binding is clearly documented both with
transfected and endogenous Type I enzymes (Hinchliffe et al., 2002). We do not yet know which
structural domains of either partner (Type I or II) are involved in this interaction. The regions involved
in heterodimerization between PtdIns5P 4-kinases IIa, IIb, and IIg is fairly certain: the b isoform is
a homodimer in the crystals used for structural analysis, with the interaction between the monomers
being due to two opposing b-pleated sheets (Rao et al., 1998), and this part of the enzyme is identical
in all three isoforms. But a crucial question is whether a hetero (or homo) dimerized Type II PtdIns5P
4-kinase is capable of also associating with a Type I PtdInd4P 5-kinase, or, put another way, does the
Type I/II association involve the same region of the enzymes so that a Type II enzyme is compelled to
associate either with a Type I or a Type II PtdInsP kinase, but not with both?
This is not a trivial question, as one of the interesting ideas that we discussed above is that the
localization of the highly active Type IIa PtdIns5P 4-kinase may be governed entirely by the relative
levels of expression of the IIb and IIg isoforms, levels that can vary greatly between tissues (Clarke et al.,
2008). If we have to factor into that idea the relative levels of the three Type I PtdIns4P 5-kinases, each
of which can interact with the Type IIa PtdIns5P 4-kinase (Hinchliffe et al., 2002) (and we do not yet
know if Type IIb or IIg can interact with Type I activities), we have a very complex picture. Indeed, such
a proposal would seem to make a nonsense of the above idea that relative levels of the three Type II
isoforms has physiological relevance in dictating their localization, and the whole process of PtdInsP
kinases associating would have to be tightly and complicatedly regulated. We should add that, when
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mass spectroscopy, so any Type I/II interaction must be of lower afﬁnity than Type II/II interactions.
Overall we feel that a more likely idea is that the domains by which Type II enzymes interact with each
other (Rao et al., 1998) are different from those that PtdIns5P 4-kinase IIa uses to associate with Type I
enzymes, and so a Type II PtdInsP 4-kinase homo or heterodimer can additionally associate with
a (two?) Type I PtdIns4P 5-kinase enzyme molecule(s). The functional consequences of this latter
association still elude us.
Summary
Our recent studies of the Type II PtdIns5P 4-kinases have revealed that the Type IIa isoform is very
muchmore active than the IIb or IIg isoforms, and that it can (and does physiologically) heterodimerize
with them. This suggests the idea that the Type IIa enzyme is targeted to the nucleus (by dimerization
with Type IIb), to secretory/transport vesicles (by dimerization with Type IIg), or to the cytoplasm (as
a homodimer), with the relative proportions of PtdIns5P 4-kinase activity at these localizations being
regulated by the relative amounts of the three Type II isoforms expressed in any cell. The targeting to
vesicles by PtdIns5P 4-kinase IIg is likely to be of particular signiﬁcance in epithelial cells in speciﬁc
regions of the kidney tubules and in a sub-population of neurons in the brain and the spinal cord. The
relationship between this dimerization between Type II PtdIns5P 4-kinase isoforms and the known
ability of Type IIa PtdIns5P 4-kinase to associatewith Type I PtdIns4P 5-kinases remains to be explored.Acknowledgements
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